Get the Stockscreener App
46.30
1.40%
0.64
After Hours:
46.30
Bridgebio Pharma Inc stock is traded at $46.30, with a volume of 1.51M.
It is up +1.40% in the last 24 hours and up +4.33% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$45.66
Open:
$45.61
24h Volume:
1.51M
Relative Volume:
0.50
Market Cap:
$8.79B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-19.21
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
-0.45%
1M Performance:
+4.33%
6M Performance:
+23.17%
1Y Performance:
+73.41%
1-Day Range:
$45.27
$46.41
1-Week Range:
$45.27
$47.40
52-Week Range:
$21.72
$48.68
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
46.30 | 8.67B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jul-09-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT - MSN
Why BridgeBio Pharma Inc. stock is on top investor watchlistsFree Consultation - jammulinksnews.com
Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy - MSN
What drives BridgeBio Pharma Inc. stock priceFree Stock Market Query - PrintWeekIndia
Bridgebio Pharma shares rise 1.97% premarket after novel human genetics evidence confirms estimates of genetic prevalence and underdiagnosis of ADH1. - AInvest
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen - Insider Monkey
Groundbreaking Genetics Study Uncovers 25,000 Hidden ADH1 Cases in US and EU, Most Patients Undiagnosed - Stock Titan
BridgeBio Pharma Inc. Stock Analysis and ForecastConsistently profitable trades - jammulinksnews.com
Is BridgeBio Pharma Inc. a good long term investmentOutstanding risk-reward balance - jammulinksnews.com
What analysts say about BridgeBio Pharma Inc. stockRobust investment performance - jammulinksnews.com
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET - The Manila Times
BridgeBio Pharma, Inc. Scheduled to Release Q2 Financial Results and Business Updates on August 5, 2025 - Nasdaq
Truist Securities Initiates Coverage on BridgeBio Pharma with 'Buy' Rating and $66 Price Target - AInvest
BridgeBio Pharma Stock (BBIO) Opinions on Analyst Buy Ratings and Attruby Launch - Quiver Quantitative
BridgeBio stock initiated with Buy rating at Truist on strong Attruby launch - Investing.com Canada
BridgeBio Pharma (BBIO) Receives New 'Buy' Rating from Truist Se - GuruFocus
BridgeBio Pharma stock maintains Buy rating at H.C. Wainwright after royalty deal - Investing.com Canada
These 2 Momentum Stocks Got a Bullish Nod — Here’s Why They Could Reach New Highs - The Globe and Mail
Jefferies Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $70 - 富途牛牛
Scotiabank Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
Citi reiterates Buy rating on BridgeBio stock ahead of key trial data - Investing.com Canada
Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com
BridgeBio Pharma (BBIO) Receives Buy Rating from Jefferies | BBIO Stock News - GuruFocus
Citi Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $67 - 富途牛牛
Jefferies Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - MSN
BridgeBio Pharma stock initiated with Buy rating at Jefferies on Attruby potential - Investing.com Canada
BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA - MSN
BridgeBio Pharma's BBP-418: A Promising Investment in Groundbreaking LGMD2I/R9 Therapy - AInvest
BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights - MSN
Helix shareholders to vote on BridgeBio Oncology merger on August 4 By Investing.com - Investing.com Nigeria
Helix shareholders to vote on BridgeBio Oncology merger on August 4 - Investing.com Australia
Cancer-Focused BridgeBio's $949M SPAC Deal Gets SEC Nod - Law360
BridgeBio Oncology's SPAC Merger Advances: SEC Clears Path for Novel Cancer Drug Development Platform - Stock Titan
BridgeBio Pharma stock hits 52-week high, reaching $45.53 By Investing.com - Investing.com South Africa
BridgeBio Pharma Inc. Rockets on Strategic Moves - StocksToTrade
BridgeBio Pharma stock hits 52-week high, reaching $45.53 - Investing.com Australia
Oppenheimer Upgrades BridgeBio Pharma to Outperform From Market Perform, Price Target is $60 - MarketScreener
BridgeBio Pharma (BBIO) Receives Rating Upgrade to Outperform | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Shares Upgraded with Positive Outlook on Future Sales | BBIO Stock News - GuruFocus
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):